How OncoSil Medical’s Record Sales and European Expansion Are Reshaping Pancreatic Cancer Treatment

Record Dose Sales Drive Momentum

OncoSil Medical Limited (ASX – OSL) has delivered a standout performance in the second quarter of fiscal 2026, reporting record dose sales that reflect a 60% increase in unit volumes compared to the same period last year. This surge translated into a 70% year-on-year revenue growth, underscoring the company’s accelerating commercial traction in the competitive medical device sector focused on pancreatic cancer treatment.

CEO Nigel Lange highlighted the quarter as pivotal, noting that the growth was driven by expanding clinical adoption and commercial activity. The company’s innovative OncoSil™ device, designed to deliver targeted radiation therapy directly into pancreatic tumours, continues to gain clinical confidence and market presence.

European Expansion Marks Key Milestones

OncoSil Medical achieved significant commercial milestones with its first patient treatments in three major European markets – Portugal, Germany, and the United Kingdom. The inaugural treatment at Instituto Português de Oncologia do Porto in Portugal, a leading cancer centre, marked a critical step in broadening patient access.

Similarly, the first commercial use in Germany’s Universitätsklinikum Augsburg opened the door to Europe’s largest healthcare market, while the UK’s Southampton General Hospital transitioned the device from clinical evaluation to routine commercial use. These milestones demonstrate OncoSil’s strategic commitment to expanding its footprint across Europe’s key healthcare systems.

Encouraging Clinical Data from OSPREY Registry

The interim analysis from the OSPREY Pancreatic Cancer Post-Marketing Clinical Registry, encompassing 64 patients treated across 19 European centres, revealed promising survival outcomes. Median overall survival for first-line patients was reported at over 20 months from diagnosis, a notable figure in the context of unresectable locally advanced pancreatic cancer.

The safety profile was favourable, with only mild adverse device events reported and no serious complications such as pancreatitis or hospital admissions. These findings, to be presented at the upcoming ESGE Days congress in Milan, reinforce the therapeutic potential of OncoSil™ in real-world clinical practice.

Manufacturing Capability Strengthened

OncoSil Medical successfully completed its first hot production test run at its new Sydney manufacturing facility, a critical step towards regulatory approval expected in the second half of 2026. This achievement not only validates the facility’s capability to produce the device under full production conditions but also aligns with the company’s strategy to enhance supply chain resilience and reduce production costs over time.

Such manufacturing advancements are essential for supporting the company’s long-term growth ambitions and improving gross product margins.

Financial Position and Leadership Changes

Financially, the company reported a decrease in operating cash outflows due to disciplined cost management and improved efficiencies. Although cash reserves fell to $2.9 million by the end of December 2025, a subsequent $1.8 million R&D tax incentive refund boosted proforma cash to $4.7 million.

On the governance front, Non-Executive Director and former Chair Douglas Cubbin retired in November 2025, with the company expressing gratitude for his leadership during his tenure.